Amgen Inc. (FRA:AMG)
Germany
· Delayed Price · Currency is EUR | Market Cap | 152.70B |
| Revenue (ttm) | 30.66B |
| Net Income (ttm) | 5.97B |
| Shares Out | n/a |
| EPS (ttm) | 11.02 |
| PE Ratio | 25.58 |
| Forward PE | 15.92 |
| Dividend | 8.52 (2.87%) |
| Ex-Dividend Date | Nov 21, 2025 |
| Volume | n/a |
| Average Volume | 95 |
| Open | 291.30 |
| Previous Close | 294.35 |
| Day's Range | 290.10 - 291.90 |
| 52-Week Range | 230.00 - 304.75 |
| Beta | n/a |
| RSI | 62.09 |
| Earnings Date | Feb 3, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
Amgen Inc at Evercore ISI Healthcare Conference Transcript
Amgen Inc at Evercore ISI Healthcare Conference Transcript
Amgen Inc at Citi Global Healthcare Conference Transcript
Amgen Inc at Citi Global Healthcare Conference Transcript
Amgen: Stagnation And The IRS Are Coming
Amgen (AMGN) is at risk of long-term stagnation due to an impending patent cliff and limited pipeline catalysts.
Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript
AMGN Factor-Based Stock Analysis
Below is Validea's guru fundamental report for AMGEN INC (AMGN). Of the 22 guru strategies we follow, AMGN rates highest using our Multi-Factor Investor model based on the published strategy of Pim va...
BMO Capital Raises Price Target for Amgen (AMGN) to $372, Maintains 'Outperform' | AMGN Stock News
BMO Capital Raises Price Target for Amgen (AMGN) to $372, Maintains 'Outperform' | AMGN Stock News
2 Dividend Stocks to Double Up On Right Now
Coca-Cola is showing why it has increased its dividend for 63 consecutive years. Amgen should maintain its strong dividend program despite some patent cliffs.
SCHD: Tops Dividend Competitors On Value, Yield, And Sustainability
SCHD's top holdings, including Merck and Amgen, combine strong profitability, sustainable payout ratios, and attractive valuations. Read why SCHD ETF is a Buy.
Biocon Biologics secures market pathway for Denosumab Biosimilars in Europe following settlement with Amgen
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced that it has finalized...
Noteworthy Monday Option Activity: AMGN, NLY, CRM
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Amgen Inc (Symbol: AMGN), where a total of 16,674 contracts have traded so far, representin...
Is the Market Bullish or Bearish on Amgen Inc?
Amgen Inc's (NYSE: AMGN) short interest as a percent of float has risen 16.82% since its last report. According to exchange reported data, there are now 13.43 million shares sold short , which is 2.5...
AMGN Up Almost 16% in a Month: Should You Buy, Sell or Hold the Stock?
Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.
Dogs Of The Dow Continue Outperforming Broader Market
Through the end of November, the year-to-date total return of the Dogs of the Dow equals 20.96%, outpacing the Dow Jones Industrial Average return of 13.86% and outpacing the broader S&P 500 Index ret...
Amgen (AMGN) Stock Signal: Is There More Room to the Upside? - 27 November 2025
Full FDA approval for one of its drugs, an excellent earnings report, and a deep pipeline support the bullish trend. Is there more room to the upside for Amgen?
Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital's Yaffee
Len Yaffee, Kessef Capital, join 'Fast Money' to talk Amgen's obesity drug, Eli Lilly's current stock action, and much more.
Notable ETF Inflow Detected - QQQI, TMUS, QCOM, AMGN
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Neos Nasdaq-100 High Income ETF (Symbol: QQQI) where we have detected ...
The Zacks Analyst Blog NVIDIA, AT&T and Amgen
NVIDIA, AT&T, and Amgen outperform peers as AI growth, 5G expansion, and strong drug sales drive investor optimism.
Top Analyst Reports for NVIDIA, AT&T & Amgen
NVIDIA's data center gains, AT&T's wireless momentum, and Amgen's product strength headline today's standout analyst reports.
Here's How Much You Would Have Made Owning Amgen Stock In The Last 15 Years
Amgen (NASDAQ: AMGN) has outperformed the market over the past 15 years by 1.0% on an annualized basis producing an average annual return of 13.12%. Currently, Amgen has a market capitalization of $1...
AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Nov. 24, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2025 Global Healthcare Conference at 1:45 p.m.
AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE
THOUSAND OAKS, Calif. , Nov. 24, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 8th annual Evercore ISI HealthCONx Conference at 10:00 a.m.
Amgen (AMGN) Rating Update: Truist Securities Raises Price Target | AMGN Stock News
Amgen (AMGN) Rating Update: Truist Securities Raises Price Target | AMGN Stock News
European Commission Approves Alvotech's AVT03 As A Biosimilar To Prolia And Xgeva
(RTTNews) - Alvotech (ALVO) announced that the European Commission has approved AVT03, a biosimilar to Amgen's Prolia and Xgeva for use across Europe.
Amgen Shines As Medical Sector Benefits From Sector Rotation
Despite low relative strength, medical stocks had solid entries in a choppy market.